BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 17139319)

  • 1. Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery.
    Cooney MM; van Heeckeren W; Bhakta S; Ortiz J; Remick SC
    Nat Clin Pract Oncol; 2006 Dec; 3(12):682-92. PubMed ID: 17139319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular damaging agents.
    Patterson DM; Rustin GJ
    Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):443-56. PubMed ID: 17459681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiangiogenic and vascular-disrupting agents in endometriosis: pitfalls and promises.
    Van Langendonckt A; Donnez J; Defrère S; Dunselman GA; Groothuis PG
    Mol Hum Reprod; 2008 May; 14(5):259-68. PubMed ID: 18430758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenesis: an update and potential drug approaches (review).
    Abdelrahim M; Konduri S; Basha R; Philip PA; Baker CH
    Int J Oncol; 2010 Jan; 36(1):5-18. PubMed ID: 19956828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current development status of small-molecule vascular disrupting agents.
    Chaplin DJ; Horsman MR; Siemann DW
    Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenesis and vascular targeting: relevance for hyperthermia.
    Horsman MR
    Int J Hyperthermia; 2008 Feb; 24(1):57-65. PubMed ID: 18214769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular disrupting agents.
    Pilat MJ; Lorusso PM
    J Cell Biochem; 2006 Nov; 99(4):1021-39. PubMed ID: 16927308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular targeting therapy: potential benefit depends on tumor and host related effects.
    Horsman MR; Bohn AB; Busk M
    Exp Oncol; 2010 Sep; 32(3):143-8. PubMed ID: 21403608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.
    Head M; Jameson MB
    Expert Opin Investig Drugs; 2010 Feb; 19(2):295-304. PubMed ID: 20050824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applying gold nanoparticles as tumor-vascular disrupting agents during brachytherapy: estimation of endothelial dose enhancement.
    Ngwa W; Makrigiorgos GM; Berbeco RI
    Phys Med Biol; 2010 Nov; 55(21):6533-48. PubMed ID: 20959684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.
    McKeage MJ; Baguley BC
    Cancer; 2010 Apr; 116(8):1859-71. PubMed ID: 20166210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular-disrupting agents in oncology.
    Mita MM; Sargsyan L; Mita AC; Spear M
    Expert Opin Investig Drugs; 2013 Mar; 22(3):317-28. PubMed ID: 23316880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular disrupting agents.
    Lippert JW
    Bioorg Med Chem; 2007 Jan; 15(2):605-15. PubMed ID: 17070061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical studies of the novel vascular disrupting agent MN-029.
    Shi W; Siemann DW
    Anticancer Res; 2005; 25(6B):3899-904. PubMed ID: 16309177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer.
    Gridelli C; Rossi A; Maione P; Rossi E; Castaldo V; Sacco PC; Colantuoni G
    Oncologist; 2009 Jun; 14(6):612-20. PubMed ID: 19474164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in tumor vasculature targeting using liposomal drug delivery systems.
    Abu Lila AS; Ishida T; Kiwada H
    Expert Opin Drug Deliv; 2009 Dec; 6(12):1297-309. PubMed ID: 19780711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential role of vascular targeted therapy to combat against tumor.
    Chen B; Jin H; Wu K
    Expert Opin Drug Deliv; 2009 Jul; 6(7):719-26. PubMed ID: 19538038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular disrupting agents: a new class of drug in cancer therapy.
    Gaya AM; Rustin GJ
    Clin Oncol (R Coll Radiol); 2005 Jun; 17(4):277-90. PubMed ID: 15997924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.
    Horsman MR; Siemann DW
    Cancer Res; 2006 Dec; 66(24):11520-39. PubMed ID: 17178843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumoral angiogenesis: review of the literature.
    Khosravi Shahi P; Fernández Pineda I
    Cancer Invest; 2008 Feb; 26(1):104-8. PubMed ID: 18181052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.